Orthocell’s Striate+™ dental membrane, which facilitates high quality and efficient bone and tissue repair, is gaining commercial momentum.
The Company’s strategy to engage key-opinion-leaders (KOLs) to drive product awareness and uptake of Striate+™ in key global health markets is progressing well. Product sales of Striate+™ from the US KOL’s alone has reached over 1,500 units.
Approvals are now in place to upgrade our Perth-based manufacturing facility with capacity to produce more than 100,000 units per annum. Commissioning of the manufacturing facility is expected in Q4 CY2022. A big win for Orthocell and Australia’s biomanufacturing sector.
Click here to read today’s ASX release.